Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.

W GulliverA AlaviM C WisemanM J GooderhamJ RaoM S AlamKim A PappO DesjardinsC Jean

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)

The effectiveness of adalimumab was maintained during this 1-year period, and an optimal gain was documented for patients with medium and high AN counts. These real-world data support a prompt treatment of HS patients and the use of IHS4 to monitor treatment.

Keyphrases

hidradenitis suppurativa
randomized controlled trial
end stage renal disease
rheumatoid arthritis

systematic review
newly diagnosed
ejection fraction
chronic kidney disease

prognostic factors
peritoneal dialysis
combination therapy
machine learning

systemic lupus erythematosus
big data
patient reported outcomes
smoking cessation